Genmab today announced that it has extended its development deal with Janssen for access to the former's DuoBody platform. Genmab will receive $2M upfront payments for up to 10 more programs. Additionally, it could net maximum milestone and licensing fees up to $219 M if all programs reached commercialization (yeah right). Any commercial products will also spawn royalties.
This new agreement essentially doubels the numbers of bi-specific antibodies that Janssen can choose to pursue. Janssen may have interests in applying these to cancer, autoimmune, infectious diseases and CNS diseases. Bi-specific antibodies dual targeting mechanism may improve both specificity and efficacy against disease targets. See FirstwordPharma.
Posted by Bruce Lehr Dec 4th 2013.